These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29032704)

  • 1. Addressing Barriers to Clozapine Underutilization: A National Effort.
    Kelly DL; Freudenreich O; Sayer MA; Love RC
    Psychiatr Serv; 2018 Feb; 69(2):224-227. PubMed ID: 29032704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management.
    Kelly DL; Love RC
    Ment Health Clin; 2019 Mar; 9(2):64-69. PubMed ID: 30842912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Professional perception of clozapine use in patients with dual psychosis.
    Grau-López L; Szerman N; Torrens M; Basurte I; Vega P; Martínez-Raga J; Casas M; Roncero C
    Actas Esp Psiquiatr; 2020 May; 48(3):99-105. PubMed ID: 32905602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community Evidence of Clozapine's Effectiveness.
    Marder SR
    Am J Psychiatry; 2016 Feb; 173(2):103-4. PubMed ID: 26844790
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis.
    Small JG; Milstein V; Marhenke JD; Hall DD; Kellams JJ
    J Clin Psychiatry; 1987 Jul; 48(7):263-7. PubMed ID: 2885310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early use of clozapine for poorly responding first-episode psychosis.
    Agid O; Remington G; Kapur S; Arenovich T; Zipursky RB
    J Clin Psychopharmacol; 2007 Aug; 27(4):369-73. PubMed ID: 17632221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing treatment with clozapine.
    Conley RR
    J Clin Psychiatry; 1998; 59 Suppl 3():44-8. PubMed ID: 9541338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study.
    Bioque M; Parellada E; García-Rizo C; Amoretti S; Fortea A; Oriolo G; Palau P; Boix-Quintana E; Safont G; Bernardo M
    Eur Psychiatry; 2020 Jul; 63(1):e71. PubMed ID: 32669145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychiatrists' attitude towards and knowledge of clozapine treatment.
    Nielsen J; Dahm M; Lublin H; Taylor D
    J Psychopharmacol; 2010 Jul; 24(7):965-71. PubMed ID: 19164499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine's Effect on Recidivism Among Offenders with Mental Disorders.
    Mela M; Depiang G
    J Am Acad Psychiatry Law; 2016 Mar; 44(1):82-90. PubMed ID: 26944747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.
    Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine prescribing barriers in the management of treatment-resistant schizophrenia: A systematic review.
    Baig AI; Bazargan-Hejazi S; Ebrahim G; Rodriguez-Lara J
    Medicine (Baltimore); 2021 Nov; 100(45):e27694. PubMed ID: 34766570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility and Barriers to Clozapine Use: A Joint Study of Clinicians' Attitudes From Singapore and Hong Kong.
    Zheng S; Lee J; Chan SKW
    J Clin Psychiatry; 2022 May; 83(4):. PubMed ID: 35584194
    [No Abstract]   [Full Text] [Related]  

  • 16. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A literature review.
    Thien K; O'Donoghue B
    Early Interv Psychiatry; 2019 Feb; 13(1):18-23. PubMed ID: 29984888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of the evidence of clozapine's anti-aggressive effects.
    Frogley C; Taylor D; Dickens G; Picchioni M
    Int J Neuropsychopharmacol; 2012 Oct; 15(9):1351-71. PubMed ID: 22339930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach.
    Beck K; McCutcheon R; Bloomfield MA; Gaughran F; Reis Marques T; MacCabe J; Selvaraj S; Taylor D; Howes OD
    Acta Psychiatr Scand; 2014 Dec; 130(6):427-38. PubMed ID: 25201058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clozapine as treatment of first choice in first psychotic episodes. What do we know?
    Vera I; Rezende L; Molina V; Sanz-Fuentenebro J
    Actas Esp Psiquiatr; 2012; 40(5):281-9. PubMed ID: 23076611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone augmentation of clozapine.
    McCarthy RH; Terkelsen KG
    Pharmacopsychiatry; 1995 Mar; 28(2):61-3. PubMed ID: 7542786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.